Curis (CRIS) Prices 6.45M Registered Direct Offering at $2.52/Unit

Curis, Inc. (NASDAQ: CRIS) announced today that it has priced a registered direct offering of 6,449,288 units, at a price of $2.52 per unit, for gross proceeds of $16.25 million before deducting placement agents’ fees and estimated offering expenses. Each unit consists of one share of the company's common stock and a warrant to buy 0.25 of a share of the company's common stock. The warrants will be exercisable for a period of five years beginning on the date of issuance, at an exercise price of $3.55 per share. The closing of the offering is expected to take place on or about January 27, 2010, subject to the satisfaction of customary closing conditions. RBC Capital Markets is acting as the sole lead placement agent and Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM - News), as co-agent in this offering.

The company intends to use the net proceeds of the offering for general corporate purposes, including but not limited to conducting further preclinical testing and clinical studies of its product candidates, including CUDC-101, and its other proprietary targeted cancer small molecule compounds; for capital expenditures; and working capital.